SNDL Inc.
NASDAQ:SNDL · NASDAQ Capital Market
-$0.03 today
Vol 2.04M · Avg 2.21M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SNDL · Revenue to Net Income
Key Ratios
Analysis
$937.4M of revenue converted into -$11.0M of net income for the selected period. Gross margin is 27.2% and net margin is -1.4%, showing how much revenue survives after costs and taxes. EPS is $-0.05, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $946.4M +2.8% | $920.4M +1.3% | $909.0M +27.6% | $712.2M +1168.9% | $56.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $687.8M +1.1% | $680.1M -5.4% | $718.6M +25.7% | $571.8M +778.0% | $65.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $258.6M +7.6% | $240.3M +26.2% | $190.4M +35.6% | $140.4M +1659.5% | -$9.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 27.3% +1.2pp | 26.1% +5.2pp | 20.9% +1.2pp | 19.7% +35.7pp | -16.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $489.0K +41.3% | $346.0K +6.8% | $324.0K -86.8% | $2.4M +0.1% | $2.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $210.6M -3.9% | $219.3M -4.7% | $230.2M +45.4% | $158.3M +185.7% | $55.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $263.1M -23.6% | $344.1M -2.7% | $353.6M -27.6% | $488.1M +289.4% | $125.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $56.3M -0.8% | $56.7M -12.7% | $64.9M +37.2% | $47.3M +365.6% | $10.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | $48.0M +216.5% | -$41.2M +58.4% | -$99.1M +69.6% | -$326.5M -45.9% | -$223.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 5.1% +9.5pp | -4.5% +6.4pp | -10.9% +34.9pp | -45.9% +352.8pp | -398.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$4.4M +95.7% | -$103.8M +36.4% | -$163.2M +53.1% | -$347.8M -158.8% | -$134.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -0.5% +10.8pp | -11.3% +6.7pp | -18.0% +30.9pp | -48.8% +190.6pp | -239.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $8.0M -50.9% | $16.4M +6.7% | $15.4M -12.8% | $17.6M +28.4% | $13.7M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.5M -2.3% | $7.7M -2.8% | $7.9M +34.2% | $5.9M +660.7% | $776.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$11.4M -531.4% | -$1.8M +79.7% | -$8.8M +72.4% | -$32.0M +68.1% | -$100.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$15.8M +85.1% | -$105.6M +38.6% | -$172.0M +54.7% | -$379.8M -61.8% | -$234.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1.7% +9.8pp | -11.5% +7.4pp | -18.9% +34.4pp | -53.3% +364.8pp | -418.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 +100.0% | -$9.4M | $0 +100.0% | -$7.3M +7.2% | -$7.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$15.8M +83.4% | -$94.8M +45.1% | -$172.7M +48.5% | -$335.1M -47.6% | -$227.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -1.7% +8.6pp | -10.3% +8.7pp | -19.0% +28.1pp | -47.1% +357.4pp | -404.4% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +84.1% | -$0 +41.6% | -$1 +57.0% | -$2 -21.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +84.1% | -$0 +41.6% | -$1 +57.0% | -$2 -21.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $258.1M -2.3% | $264.2M +1.9% | $259.4M +12.8% | $229.9M +23.6% | $186.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $258.1M -2.3% | $264.2M +1.9% | $259.4M +12.8% | $229.9M +23.6% | $186.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
COMPASS Pathways plc
NASDAQ:CMPS
$1.20B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$992.27M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$807.09M
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$658.03M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$460.95M
Evolus, Inc.
NASDAQ:EOLS
$434.31M
Emergent BioSolutions Inc.
NYSE:EBS
$410.96M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$309.57M
SIGA Technologies, Inc.
NASDAQ:SIGA
$308.05M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$276.31M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SNDL generate?
SNDL Inc. (SNDL) reported $946.40M of revenue in fiscal 2025.
Is SNDL profitable?
SNDL Inc. (SNDL) reported -$15,774,000.00 of net income, with a net margin of -1.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.